Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

Company Overview - Novo Nordisk is collaborating with WeightWatchers to enhance accessibility to care for individuals with chronic obesity, leveraging WeightWatchers' six decades of experience in weight management [1] - The company is introducing a new cash-offer price for its Wegovy® medication, starting at $299 for self-paying patients from July 1, 2025, which is an increase from the previous $199 offer [1][16] - Novo Nordisk has filed nearly 120 lawsuits across 34 states against entities unlawfully marketing or selling knockoff drugs, emphasizing its commitment to patient safety [3] Industry Context - Approximately 40% of adults in the U.S. are living with obesity, highlighting the public health implications and the need for effective long-term management solutions [5] - The FDA has issued warnings regarding the risks associated with poor quality compounded drugs, particularly knockoff "semaglutide," which can lead to serious health issues [3] - Obesity is recognized as a chronic disease influenced by various factors, including genetics and social determinants of health, rather than merely a lack of willpower [4]